CD86 and Sepsis: In addition, breast cancer and sepsis HLA-DRlow/- monocytes, when compared to HLA-DR++ monocytes, displayed significantly reduced levels of the co-receptors CD86, CD80 and the suggested anti-inflammatory monocyte-macrophage marker CD163 (Fig 2C) [41].